SOBI 'temporarily' withdraws Orfadin oral suspension NDA on FDA info request
This article was originally published in Scrip
Swedish Orphan Biovitrum, better known as SOBI, on 27 December disclosed it was withdrawing its new drug application (NDA) for Orfadin (nitisinone) oral suspension in the US, owing the decision to the FDA's request for more information about the usability of the product by the intended population the oral syringe that will be included in the packaging.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.